• Explore /
  • Poster
  • / Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.

Phase 1 dose escalation, food effect, and biomarker study of RG7388, a more potent second-generation MDM2 antagonist, in patients (pts) with solid tumors.

Abstract Poster

Authors

Lillian Siu

Lillian L. Siu

Princess Margaret Cancer Centre, Toronto, ON, Canada

Lillian L. Siu , Antoine Italiano , Wilson H. Miller Jr., Jean-Yves Blay , Jourik A. Gietema , Yung-Jue Bang , Linda R. Mileshkin , Hal W. Hirte , Monica Reckner , Brian Higgins , Lori Jukofsky , Steven Blotner , Jianguo Zhi , Steven Middleton , Gwen L. Nichols , Lin Chi Chen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Developmental Therapeutics: Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Cytotoxic and Other Novel Agents

Clinical Trial Registration Number

NCT01462175

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 2535)

DOI

10.1200/jco.2014.32.15_suppl.2535

Abstract #

2535

Poster Bd #

50

Abstract Disclosures

Similar Posters

First Author: Anthony W. Tolcher

First Author: Todd Michael Bauer

First Author: Geoffrey Shapiro

First Author: Soohyeon Lee